EUVIMEDObjevte EUVIMED
Open access

Negative cooperativity drives activity of capsid-directed antivirals against hepatitis B virus

Caleb J Valkner iD, Nora Gibes iD, Marina Sicheng Xie iD, Smita Nair iD, Shiv Kumar, Samson Francis, Balasubramanian Venkatakrishnan iD, Irina Tsvetkova iD, Angela Patterson iD, Michael VanNieuwenhze, Bogdan Dragnea, Joseph Che-Yen Wang iD and 1 more

Science Advances · 2026-06-12 · 12 (24)

DOI: 10.1126/sciadv.aed6483 ↗

At a glance

Journal article in Science Advances, published on 2026-06-12. Written by Caleb J Valkner and 12 co-authors. Institution: Molecular and Cellular Biochemistry Department, Indiana University-Bloomington, Bloomington, IN 47405, USA. Major MEDLINE topics: Hepatitis B virus, Antiviral Agents, Capsid, Capsid Proteins. Cited 3 times so far (Crossref); 77 references. The full text is freely available in PubMed Central. Funded by: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Hepatitis B virus capsid protein plays a role in almost every step of viral replication, from self-assembly to genome release. This makes capsid protein an attractive target for antiviral development. Capsid assembly modulators (CAMs) are direct-acting antivirals that bind capsid protein, leading to empty or aberrant complexes instead of an infectious virus. CAMs can also disrupt the capsid, preventing new infection. To understand CAM activity, we examined the energetics of CAM-capsid interaction. We observed negative cooperativity of CAM-binding kinetics and thermodynamics. These correlate with large changes in capsid architecture that presage capsid rupture. We propose that CAMs induce an accumulated strain on the capsid. Understanding the interplay of forces and architecture will help guide the development of CAMs.

Subjects

MeSH terms (MEDLINE)

Hepatitis B virusAntiviral AgentsCapsidCapsid ProteinsVirus AssemblyProtein BindingVirus ReplicationThermodynamicsKineticsHumans

Substances

Antiviral AgentsCapsid Proteins

Authors and institutions

  • Molecular and Cellular Biochemistry Department, Indiana University-Bloomington, Bloomington, IN 47405, USA.
  • Chemistry Department, Indiana University-Bloomington, Bloomington, IN 47405, USA.
  • Door Pharmaceuticals LLC, Bloomington, IN 47405, USA.
  • Department of Cell and Biological Systems, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.

ORCID profiles: Caleb J Valkner, Nora Gibes, Marina Sicheng Xie, Smita Nair, Balasubramanian Venkatakrishnan, Irina Tsvetkova, Angela Patterson, Joseph Che-Yen Wang, Adam Zlotnick

Funding

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases

Cite

APA

Valkner, C. J., Gibes, N., Xie, M. S., Nair, S., Kumar, S., Francis, S., Venkatakrishnan, B., Tsvetkova, I., Patterson, A., VanNieuwenhze, M., Dragnea, B., Wang, J. C., & Zlotnick, A. (2026). Negative cooperativity drives activity of capsid-directed antivirals against hepatitis B virus. Science Advances, 12(24). https://doi.org/10.1126/sciadv.aed6483

Vancouver

Valkner CJ, Gibes N, Xie MS, Nair S, Kumar S, Francis S, et al. Negative cooperativity drives activity of capsid-directed antivirals against hepatitis B virus. Science Advances. 2026;12(24). doi:10.1126/sciadv.aed6483

BibTeX
@article{Valkner2026,
  author = {Valkner, Caleb J and Gibes, Nora and Xie, Marina Sicheng and Nair, Smita and Kumar, Shiv and Francis, Samson and Venkatakrishnan, Balasubramanian and Tsvetkova, Irina and Patterson, Angela and VanNieuwenhze, Michael and Dragnea, Bogdan and Wang, Joseph Che-Yen and Zlotnick, Adam},
  title = {Negative cooperativity drives activity of capsid-directed antivirals against hepatitis B virus},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {24},
  doi = {10.1126/sciadv.aed6483}
}
Start for free →